Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 19/20 | 0.40 |
| ▸ | CCR5 | P51681 | 12/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3944847 | 1.00 | CCR2 (0.40) | CCR2CCR5KCNH2KDM4E | |
| SCHEMBL3943941 | 1.00 | CCR2 (0.40) | CCR2CCR5KCNH2KDM4E | |
| SCHEMBL3943951 | 1.00 | CCR2 (0.40) | CCR2CCR5KCNH2KDM4E | |
| SCHEMBL2347863 | 1.00 | CCR2 (0.40) | CCR2CCR5KCNH2KDM4E | |
| SCHEMBL3743758 | 0.81 | CCR2 (0.36) | CCR2CCR5KCNH2 | |
| SCHEMBL3743751 | 0.81 | CCR2 (0.36) | CCR2CCR5KCNH2 | |
| SCHEMBL13600779 | 0.81 | CASP3 (0.45) | — | |
| SCHEMBL3741481 | 0.80 | CCR2 (0.36) | CCR2CCR5KCNH2 | |
| SCHEMBL2786216 | 0.79 | CCR2 (0.52) | CCR2CCR5KCNH2 | |
| SCHEMBL2786223 | 0.79 | CCR2 (0.52) | CCR2CCR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194051-B1 | Process for preparing compounds useful as intermediates for the preparation of modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2011-08-31 | — | — | EP | claimed |
| EP-2194051-A1 | Process for preparing compounds useful as intermediates for the preparation of modulators of chemokine receptor activity | Bristol-Myers Squibb Company (US) | 2010-06-09 | — | — | EP | claimed |
| US-20100113489-A1 | MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY, CRYSTALLINE FORMS AND PROCESS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | claimed |
| US-20080027084-A1 | MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CRYSTALLINE FORMS AND PROCESS | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-31 | — | — | US | claimed |
| EP-2049519-B9 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2194051-A1 | Process for preparing compounds useful as intermediates for the preparation of modulators of chemokine receptor activity | Bristol-Myers Squibb Company (US) | 2010-06-09 | — | — | EP | disclosed |
| EP-2049519-B1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20100113489-A1 | MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY, CRYSTALLINE FORMS AND PROCESS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
| US-7687508-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-30 | — | — | US | disclosed |
| US-7629351-B2 | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080027084-A1 | MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CRYSTALLINE FORMS AND PROCESS | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-31 | — | — | US | disclosed |
| US-20080027080-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027084-A1 | MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CRYSTALLINE FORMS AND PROCESS | ACKR3, CCR1, CXCR1 | CCR2 4/4885CCR5 7/4885KCNH2 2383/4885 |
| US-20080027080-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR5, CXCR4, CCR7 | CCR2 5/4885CCR5 1/4885KCNH2 4062/4885 |
| US-20100113489-A1 | MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY, CRYSTALLINE FORMS AND PROCESS | ACKR3, CCR1, CCR2 | CCR2 3/4885CCR5 7/4885KCNH2 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.